Insulet (PODD) Revenue Growth (3y) (2013 - 2026)
Insulet (PODD) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.63% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 8.01% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 4.70% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 15.36% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 10.52% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 17.14% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 2.92% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 0.73% |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 28.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.61% |
| Dec 31, 2025 | 28.47% |
| Sep 30, 2025 | 27.50% |
| Jun 30, 2025 | 29.43% |
| Mar 31, 2025 | 24.42% |
| Dec 31, 2024 | 24.76% |
| Sep 30, 2024 | 27.60% |
| Jun 30, 2024 | 23.41% |
| Mar 31, 2024 | 20.52% |
| Dec 31, 2023 | 27.48% |
| Sep 30, 2023 | 22.74% |
| Jun 30, 2023 | 20.56% |
| Mar 31, 2023 | 21.84% |
| Dec 31, 2022 | 20.86% |
| Sep 30, 2022 | 21.06% |
| Jun 30, 2022 | 19.13% |
| Mar 31, 2022 | 22.78% |
| Dec 31, 2021 | 23.11% |
| Sep 30, 2021 | 20.11% |
| Jun 30, 2021 | 27.91% |